Compare UMC & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UMC | WAT |
|---|---|---|
| Founded | 1980 | 1958 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 17.4B |
| IPO Year | 2000 | 1995 |
| Metric | UMC | WAT |
|---|---|---|
| Price | $8.00 | $394.93 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 1 | 14 |
| Target Price | N/A | ★ $382.14 |
| AVG Volume (30 Days) | ★ 8.2M | 531.7K |
| Earning Date | 01-20-2026 | 11-04-2025 |
| Dividend Yield | ★ 4.64% | N/A |
| EPS Growth | N/A | ★ 3.82 |
| EPS | 0.10 | ★ 10.88 |
| Revenue | ★ $7,746,022,974.00 | $3,105,638,000.00 |
| Revenue This Year | $3.20 | $7.96 |
| Revenue Next Year | $6.45 | $6.32 |
| P/E Ratio | ★ $14.89 | $36.30 |
| Revenue Growth | 4.08 | ★ 6.90 |
| 52 Week Low | $5.61 | $275.05 |
| 52 Week High | $8.33 | $423.56 |
| Indicator | UMC | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 66.38 | 61.33 |
| Support Level | $7.15 | $386.09 |
| Resistance Level | $7.45 | $403.80 |
| Average True Range (ATR) | 0.17 | 9.63 |
| MACD | 0.08 | -1.66 |
| Stochastic Oscillator | 94.04 | 53.55 |
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 5% market share in 2024 after TSMC and SMIC. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the us, and South Korea. UMC features a diverse customer base that includes Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx, and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.